Attentrol Capsules (Generic Strattera) - Active Ingredient And Chemical structure
The active ingredient contained in Attentrol Capsules is Atomoxetine Hydrochloride . Atomoxetine HCl is a white to practically white solid, which has a solubility of 27.8 mg/mL in water. The structure is shown below
Attentrol Capsules (Generic Strattera)- Uses
Atomoxetine Hydrochloride in the form of Generic Strattera Capsules (Attentrol Capsules) is a selective norepinephrine reuptake inhibitor used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Generic Forms and Brand names of Strattera (Atomoxetine Hydrochloride)
Attentrol manufactured by Sun Pharmaceutical Industries Ltd., India is an effective treatment for treatment of Attention Deficit Hyperactivity Disorder (ADHD). Strattera which has the active ingredient Atomoxetine Hydrochloride is also sold as Attentin, Tomoxetin and under various other brand names. Strattera (Atomoxetine HCl) is a selective norepinephrine reuptake inhibitor.
Attentrol Capsules (Generic Strattera) - Preparations
Attentrol is available as Capsules of 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg. Each capsule contains atomoxetine HCl equivalent to 10, 18, 25, 40, 60, 80, or 100 mg of atomoxetine.
Attentrol Capsules (Generic Strattera) - Storage Requirements
Attentrol Capsules are to be stored at room temperature (15°C to 30°C). Store away from heat, moisture, and light.
Attentrol Capsules (Generic Strattera) - Contraindications
Attentrol Capsules are contraindicated in the following cases:
Hypersensitivity to Atomoxetine HCl or other constituents of product. Use of Attentrol Capsules within 2 weeks after discontinuing MAOI or other drugs that affect brain monoamine concentrations. In patients with Narrow Angle Glaucoma.
Attentrol Capsules (Generic Strattera) - Dosage
The recommended starting dose of Attentrol Capsules for adults as well as Children and adolescents over 70 kg is 40 mg once a day.
Warnings And Precautions When Using Attentrol Capsules (Generic Strattera)
Suicidal Ideation - Monitor for suicidality, clinical worsening, and unusual changes in behavior.
Severe Liver Injury - Attentrol Capsules should be discontinued and not restarted in patients with jaundice or laboratory evidence of liver injury.
Serious Cardiovascular Events - Sudden death, stroke and myocardial infarction have been reported in association with atomoxetine treatment. Generic Strattera generally should not be used in children or adolescents with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm bnormalities, or other serious cardiac problems. Consideration has be given to not using Generic Strattera in adults with clinically significant cardiac abnormalities.
Emergent Cardiovascular Symptoms - Patients should undergo prompt cardiac evaluation.
Effects on Blood Pressure and Heart Rate - Can increase blood pressure and heart rate; orthostasis, syncope and Raynaud's phenomenon may occur. Use with caution in patients with hypertension, tachycardia, or cardiovascular or cerebrovascular disease.
Emergent Psychotic or Manic Symptoms - Discontinuing treatment with Attentrol Capsules should be considered if such new Psychotic or Manic Symptoms symptoms occur.
Bipolar Disorder - Patients should be screened to avoid possible induction of a mixed/manic episode.
Aggressive behavior - Aggressive behavior or hostility in patients undergoing treatment should be monitored.
Possible allergic reactions - Possible allergic reactions including anaphylactic reactions, angioneurotic edema, urticaria, and rash can occur in patients undergoing Attentrol therapy.
Effects on Urine Outflow - Urinary hesitancy and retention may occur.
Priapism - Prompt medical attention is required in the event of suspected priapism.
Growth - Height and weight should be monitored in pediatric patients. Concomitant Use of Potent CYP2D6 Inhibitors or Use in patients known to be CYP2D6 PMs may require dose adjustment of Attentrol.
Side Effects Of Attentrol Capsules (Generic Strattera)
The most common side effects of Attentrol Capsules are:
Child and Adolescent Clinical Trials - Nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence.
Adult Clinical Trials - Constipation, dry mouth, nausea, fatigue, decreased appetite, insomnia, erectile dysfunction, urinary hesitation and/or urinary retention and/or dysuria, dysmenorrhea, and hot flush.
There have been rare cases of clinically significant liver injury that were considered probably or possibly related to Strattera use in postmarketing experience. Generic Strattera (Attentrol Capsules) should be discontinued in patients with jaundice or laboratory evidence of liver injury, and should not be restarted.
